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Photodynamic therapy (PDT) was used as therapy for early neoplasia associated with 
Barrett´s oesophagus (BE). This is 5-year follow-up of patients enrolled into randomized 
controlled trial of 5-aminolaevulinic acid (ALA) vs. Photofrin PDT.  
Methods: 
Biopsies were taken from original Barrett’s segment during endoscopic follow up using 
Seattle protocol. Endoscopic mucosal resection (EMR) +/-radiofrequency ablation (RFA) was 
preferred therapy in patients who failed PDT and/or had recurrent neoplasia.  
Results: 
Fifty eight of 64 patients enrolled in the original trial were followed up including 31 patients 
treated with ALA PDT (17 patients with ≤6cm, 14 patients with ˃6cm segment of BE) and 27 
treated with Photofrin PDT (14 patients with ≤6cm, 13 patients with ˃6cm BE). Initial 
success was achieved in 65% (20/31) ALA and 48% (13/27) Phototofrin patients, (p=0.289). 
35% patients (7/20) relapsed in ALA group and 54% (7/13) relapsed in Photofrin group 
(p=0.472). At a median follow-up of 67 months, no significant difference was found in long 
term complete reversal of intestinal metaplasia (CR-IM) and complete reversal of dysplasia 
(CR-D) between ALA and Photofrin groups (78% vs 63%; p=0.18; 90% vs 76%; p=0.26). 
Original length of BE did not alter long-term outcome. Four patients from each group 
progressed to invasive oesophageal adenocarcinoma. Initial success of ALA PDT was 





Initial response to PDT plays key role in long term outcome. RFA +/- EMR have, however, 
become preferred minimally invasive ablative therapy for BE-related neoplasia due to poor 
efficacy of PDT.  
 



















The incidence of oesophageal adenocarcinoma (OAC) has increased rapidly in the Western 
countries in the last few decades and the 5-year survival rate remains still poor at only 15% 
[1]. Barrett´s esophagus (BE) represents a pre-malignant condition leading to OAC [2]. Until 
recently, oesophagectomy was standard therapy for both invasive OAC and early neoplasia 
arising in BE including intramucosal carcinoma and high grade dysplasia [3]. Surgery 
performed even for early BE related neoplasia is associated with significant morbidity and 
there has been rapid progress of minimally invasive therapy in the last two decades [4-7].  
Photodynamic therapy using different photosenzitisers including porfimer sodium (Photofrin) 
[4,8], 5-aminolaevulinic acid (ALA) [9,10] or m-tetrahydroxyphenyl chlorine [11] has been 
investigated as a therapeutic option. Nevertheless, due to poor efficacy of PDT [8] and side 
effects (especially related to Photofrin) [4,8], radiofrequency ablation (RFA) in combination 
with endoscopic mucosal resection (EMR) have become preferred, first line endoscopic 
therapy for BE- related early neoplasia within the last few years [5,12-14].   
This single-centre study commenced before RFA was available and aimed to establish the 
relative merits of Photofrin and ALA PDT to treat BE-related neoplasia (high grade dysplasia 
(HGD) or intramucosal carcinoma (IMC)) [8]. The current paper reports on the long-term 
outcomes of this trial and specifically examines the outcomes of additional therapy in patients 







A total of 64 patients were enrolled into the randomized controlled trial between 2006 and 
2009 at University College London Hospital (UCLH). Thirty-four patients were 
photosensitised with ALA and 30 with Photofrin. A maximum of 2 treatment sessions, 3 
months apart, were allowed for Photofrin and 3 treatment sessions were allowed for ALA. 
ALA (DUSA Pharmaceuticals, NY, USA) was administered orally on the morning of the 
procedure at the dose of 60 mg/kg and Photofrin (Axcan Pharma) was administered 3 days 
prior to the treatment by intravenous injection into a large vein in the ante-cubital fossa at a 
dose of 2 mg/kg. Light precautions were followed and a light metre was provided. Light was 
delivered by either an 18-mm transparent plastic balloon for ALA (supplied by DUSA) or a 
bolster device for Photofrin (made by CAM, UCL). Great care was taken to ensure that there 
was no overlap when using Photofrin-PDT (for the high-potential risk of stricture formation).  
For both, ALA-PDT and Photofrin-PDT, red light (635nm) was delivered [8]. 
All patients treated with PDT received PPI before and after PDT. Since the current study is a 
long-term follow up of treatment, 3 patients from each group were excluded as no follow up 
biopsies were taken. In the ALA group, one patient was followed-up locally and no histology 
results are available; one patient developed invasive moderately differentiated 
adenocarcinoma between enrolment and initial PDT and underwent oesophagectomy; one 
patient had poorly differentiated adenocarcinoma at time of PDT and underwent 
chemoradiotherapy. In the Photofrin group, one patient died 10 days after PDT from 
Clostridium difficile infection; one patient had invasive moderately differentiated carcinoma 
at time of PDT and underwent oesophagectomy and one patient died 4 weeks after PDT from 




The patients were originally stratified by the number of treatment segments needed. A 
maximum of 6cm could be treated in each segment. A total of 17 patients from ALA group 
had a single treatment segment and 14 patients had a double segment (˃6cm) of BE treated. A 
total of 14 patients from the Photofrin group had a single segment treatment of BE and 13 
patients had a double segment treatment. All patients had high grade dysplasia in Barrett´s 
oesophagus when enrolled into the original randomised controlled trial. The follow-up data 
for this paper were censored in August 2016. 
Follow-up protocol: 
Four quadrant large-cup biopsies were taken every 2 cm throughout the original Barrett´s 
segment at 6 weeks, 4 and 12 months and then annually after completion of treatment, unless 
the discovery of persistent or recurrent neoplasia required further intervention. High-
resolution white-light endoscopy combined with either narrow-band imaging (Olympus) or i-
Scan enhancement (Pentax) was used in follow-up procedures. The Prague classification was 
used to assess BE and the revised Vienna classification was used for histological assessment 
of neoplasia [15,16].  
 
Subsequent therapy  
If BE-related neoplasia persisted despite PDT or recurred later, appropriate therapy was 
chosen: endoscopic mucosal resection (EMR) was performed if nodular non-invasive 
neoplasia was present; radiofrequency ablation (RFA) was used for flat dysplasia, in line with 
standard protocols [5]. Surgery and/or chemoradiotherapy was reserved for those with 






The original randomised controlled trial of PDT was registered at: http://www.controlled-
trials.com, number ISRCTN16444200 and approved by Berkshire Research Ethics Committee 
13/1/2006 (ref: 05/Q1602/193). RFA data come from the UK RFA registry, number 
ISRCTN93069556. National Research Ethics Service (NRES) (ref. 08/H0714/27) approved 
the RFA registry - date applied: 12/06/2013 and date assigned 14/6/2013. 
Written, informed consent was obtained from each patient included in the study. 
The procedures were in accordance with the Helsinki Declaration of 1975, as revised in 1983. 
 
Statistics: 
Data obtained were tested statistically by means of descriptive statistics, Fisher´s exact test 
and Mann Whitney test. Log-rank analysis was undertaken using Kaplan-Meier plots of 
disease-free survival. All analysis was performed using Statistica software, version 13, 2013, 





There was no statistical difference in age between the two groups tested at the time of 
randomisation: ALA: mean 69+/-9, Photofrin: mean 67 +/- 9; p=0.41. No difference in length 
of Barrett´s oesophagus [cm] between the groups was found: ALA: median 6, IQR 
(interquartile range): 4-8; Photofrin: median 4, IQR: 3-9; p=0.9. 




Results at completion of PDT: 
At the first endoscopy after completion of PDT, a statistically significant difference in CR-IM 
(complete reversal of intestinal metaplasia) was found between the groups, with ALA being 
more successful: ALA: 17/31 (55%) vs. Photofrin: 6/27 (22%); p=0.016. No difference was, 
however, found in CR-D (complete reversal of dysplasia) between the groups: ALA: 20/31 
(65%) vs. Photofrin: 13/27 (48%); p=0.289. 
 
Recurrence of Dysplasia after PDT 
Seven of the 20 patients (35%) who were initially successfully treated with ALA and 7 of 13 
with initial success after Photofrin (54%) had recurrence of dysplasia. Early and late 
recurrences occurred at similar frequencies after both ALA and Photofrin, anywhere between 
4-109 months after completion of treatment. Long-term success (complete reversal of 
dysplasia) of PDT as a single treatment modality is shown in Figure 1. The Kaplan Meier 
curve demonstrates a 68% success for ALA-PDT at 5 years compared to 60% for Photofrin. 
The difference did not reach statistical significance (Log rank p=0.428). 
Figure 2 shows the long-term success (CR-D) for all 58 patients when those who suffered a 
recurrence were treated with a non-PDT therapy. No statistically significant difference was 
found in final CR-D between the groups: the Kaplan Meier curve demonstrates a 90% success 
for ALA-PDT at 5 years compared to 76% for Photofrin, (Log rank p=0.26). Final CR-IM 
was also similar between the groups. At 5 years, the KM curve gave a predicted CR-IM rate 





Outcomes at 5 year follow up depending on original length of BE:  
No differences in CR-IM and CR-D were observed between patients with original single 
segment (≤6cm) and double segment (˃6cm) treatment, whether they were treated with ALA 
or Photofrin. Details are shown in Table 1.  
 
Outcomes depending on original success of PDT: 
A total of 13 ALA patients (13/31; 42%) and 6 Photofrin patients (6/27; 22%); p=0.161, did 
not have recurrence of dysplasia and did not receive any further therapy. Long-term success 
of PDT as mono-therapy is shown in Figure 1.  For those who failed and were treated with 
newer endoscopic therapy (EMR +/- RFA), long-term remission was also achieved in many. 
The final outcome of these patients is shown in Figure 4. Overall, initial success predicted 
long-term remission (p=0.045). This success remained statistically significant in the ALA 
group alone (p=0.03), but not in the Photofrin group alone (p=0.62).  
 
Management of Recurrent Disease or failed PDT  
Six recurrences after ALA PDT were treated with a combination of EMR and RFA, one was 
treated with radiotherapy for moderately differentiated invasive oesophageal adenocarcinoma. 
Six patients (86%) remain in remission long-term. The other has residual dysplasia.  
Six recurrences after Photofrin were treated with a combination of EMR and RFA and one did 
not receive any therapy. Four patients (57%) remain in long-term remission, three have 
residual dysplasia. 




Progression to invasive cancer: 
Eight patients (8/58; 14%) progressed to invasive cancer. Four patients belonged to the ALA 
group (all of them progressed despite endoscopic therapy; subsequently, one was treated with 
surgery and chemotherapy, two with chemoradiotherapy and one with radiotherapy), four 
patients belonged to the Photofrin group (one patient, treated endoscopically, died of 
metastatic oesophageal adenocarcinoma; two patients underwent oesophagectomy (one after 
previous EMR); one received endoscopic therapy, but was not fit for suggested palliative 
radiotherapy due to psychological conditions). Figure 5 shows time and probability of 
development of invasive cancer in ALA and Photofrin group. At 5 year follow up, the KM 
probability of developing invasive cancer was similar in both treatment groups at just below 
20%, following multimodality treatment (p=0.788).  
 
DISCUSSION: 
The aim of this study was to assess the long-term outcomes of patients with BE associated 
neoplasia who were originally enrolled into the randomised controlled trial comparing the 
photodynamic therapy drugs ALA and Photofrin [8]. 
At a median of more than 5 years follow-up, many patients who had entered remission 
initially relapsed and required further endoscopic intervention. This resulted in no statistically 
significant difference in CR-IM and CR-D between the groups treated with ALA or Photofrin. 
This differs from the situation at completion of PDT when CR-IM was significantly higher in 
ALA group. The explanation for this is clear: all failures of PDT and recurrences of dysplasia 
were treated in the same way: non-invasive neoplasia was treated endoscopically, usually by 




coagulation), invasive neoplasia was treated with chemoradiotherapy and/or surgery (minority 
of cases). Our group has documented previously, that RFA in combination with EMR is 
effective, not only in BE ablation-naive patients [5,17], but also in those for whom 
photodynamic ablative therapy failed [18]. 
When analysing the effect of multimodality treatment, there were no differences in CR-IM 
and CR-D between shorter and longer segments of BE. This again differs from the situation at 
the originally reported median follow-up of two years post-PDT. At that time, patients with 
segments of dysplastic BE <6cm in length, treated with ALA had significantly higher CR-
HGD compared to patients with longer segment treated with ALA [8]. The most likely reason 
is that RFA has a very high success rate for non-nodular dysplastic BE of any length.  
Our data show that patients treated with ALA PDT which led to reversal of dysplasia had a 
significantly better long-term outcome when compared to those who failed PDT originally. 
This finding is not replicated in the Photofrin group. This is a crucial finding and confirms the 
fact, that Barrett´s oesophagus is not just one disease, which responds to any ablative therapy 
in a uniform way. Our original study allowed up to 3 consecutive PDT treatments. We 
previously reported that if dysplasia was not cleared after the first treatement, subsequent 
PDT was less likely to lead to remission [8]. Prasad et al looked at the biomarkers of patients 
with HGD or IMC in BE who underwent PDT with Photofrin. Loss of biomarkers related to 
progression of neoplasia in BE was associated with histologic downgrading of dysplasia after 
PDT; those patients with persistent positivity of biomarkers were at higher risk of recurrent 
HGD [19]. They confirmed in another study, that p16 allelic loss predicted decreased 
response to PDT [20]. Recently, Timmer et al reported, that genetic biomarkers can predict 
achievement of CR-D after endoscopic therapy and that patients with multiple genetic 




help in the management of dysplastic BE. We have similarly demonstrated that relapse is 
related to persistence of aneuploidy after treatment within the residual Barrett’s segment [22]. 
We have also demonstrated that pro-tumorigenic mutations can be found in post-ablation 
squamous mucosa as well as in mutant deep oesophageal glands; both are associated with 
dysplasia recurrence [23]. These findings all suggest that the genetic milieu of the residual 
Barrett’s segment is more complex and other abnormalities occur prior to the onset of 
dysplasia, a phenomenon that has been described in detail by a number of groups [24,25]. 
CR-D at completion of PDT was 65% in ALA group and 48% in Photofrin group. Most of 
these patients went on immediately to endoscopic rescue therapies. Despite multiple 
recurrences, which were treated mainly with RFA +/- EMR, CR-D at a median follow-up of 
67 months has reached 77% in ALA group and 63% in Photofrin group. Therefore, in 
agreement with recent studies, combination of RFA +/-EMR seems to be an effective, durable 
and safe ablative therapy for dysplastic BE, even in those previously treated with PDT. The 
findings in this paper lend further support to the notion that EMR and RFA are better 
treatment options for patients with dysplastic BE.  RFA is also associated with less frequent 
buried metaplasia (1%) when compared to PDT (14%) and therefore possible subsequent 
development of sub-squamous neoplasia should be less likely [26]. In conclusion, PDT alone 
does not offer a valuable long-term treatment for dysplastic Barrett’s oesophagus. Endoscopic 
treatment should continue to focus on newer treatment modalities.  
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Figure 1:  Long-term success (complete reversal of dysplasia) of PDT as a single treatment 










Figure 2: Long-term success for all 58 patients (including those with PDT failure, who were 





















ALA ≤6cm  12/17 (71%) 13/17 (76%) 
ALA ˃6cm  9/14 (64%) 11/14 (79%) 
Photofrin ≤6cm  7/14 (50%) 8/14 (57%) 
Photofrin ˃6cm  6/13 (46%) 9/13 (69%) 
 
Table 1: Detailed analysis of CR-IM and CR-D of each segment of BE treated with ALA or 
















Initial Rx No failed F/U Rx modality No treated Long term remission Comments 
ALA 11 No intervention 2 1 1 residual dysplasia 
  
EMR and/or RFA 6 3 3 residual dysplasia 
  
Surgery + chemotherapy 1 0 
1 died of metastatic 
disease 
  
Chemoradiotherapy 2 1 1 residual dysplasia 
Photofrin 14 No intervention 1 0 1 residual HGD 
  
EMR and/or RFA 10 7 
2 residual dysplasia,  
1 died of metastatic 
disease 
  
Oesophagectomy 3 No follow-up biopsies No follow-up biopsies 
 









Figure 5: Long-term probability of development of  invasive cancer: χ2 = 0.072, p=0.788.  
 
 
 
 
 
 
 
